We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

First Patients are Vaccinated in IMPRINT, immatics’ Pivotal Phase III Trial with IMA901 in Patients with RCC

Product News   Jun 16, 2011

 
First Patients are Vaccinated in IMPRINT, immatics’ Pivotal Phase III Trial with IMA901 in Patients with RCC
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine

Product News

Intravacc and Celonic have announced that they have signed a research agreement to further design, develop and produce a COVID-19 vaccine based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc’s proprietary Outer Membrane Vesicle (OMV) technology.

READ MORE

Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform

Product News

Medidata is collaborating with Moderna, Inc. to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.

READ MORE

Thermo Fisher Expands GlobalAccess Sequencing Program to Oncology Labs

Product News

The company has extended program benefits to oncology laboratories and fast-tracking access to comprehensive molecular profiling on the Genexus System.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE